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Abstract N363S and ER22/23EK polymorphisms observed
within glucocorticoid receptor gene (NR3C1) may play an
important role in the development of bronchial asthma.
NR3C1 gene is associated with an altered sensitivity to GCs.
T h ea i mo ft h er e s e a r c hp r o j e c tw a st os t u d yt h ec o r r e l a t i o n
between this NR3C1 gene polymorphisms and occurrence of
asthma in the population of Polish asthmatics. Peripheral
blood was obtained from 207 healthy volunteers and 221
asthma patients. Genotyping was carried out with PCR-
RFLP method. In the groups of patients with uncontrolled
moderate asthma and uncontrolled severe disease, the geno-
type distribution for the investigated polymorphisms was as
follows: N363S-AA, AG, GG occurring with 0.881/0.073/
0.046 frequency and ER22/23EK-GG, GA, AA occurring
with 0.963/0.037/0.000 frequency. Chi-square analysis
revealed a signiﬁcantly different (P\0.05) distribution between
cases and controls for the N363S polymorphisms. The
N363S polymorphism of NR3C1 gene is signiﬁcantly
associated with bronchial asthma, susceptibility to the
development of moderate to severe form of uncontrolled
bronchial asthma.
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Introduction
Bronchial asthma is a hetereogeneous disease. The clinical
presentation is a resultant of interactions between envi-
ronmental and genetic factors [1]. Multifactor character of
etiopathogenesis of bronchial asthma results in signiﬁcant
hereditary variability of phenotypic traits [2]. It should be
emphasized that there is no single-gene model of asthma
heredity, and the correlation of changes within a single
gene with the clinical presentation is difﬁcult to determine
[3–5]. The role of genetic factors in etiopathogenesis of
bronchial asthma is currently estimated to range from 36 to
94% [4, 6]. Studies of the human genome focus on ca. 100
loci, which may correlate with chronic inﬂammatory pro-
cesses in the respiratory tract, atopy, bronchiolar hyperre-
activity and production of inﬂammatory mediators [1].
Hereditary variability and structural changes within the
single gene demonstrate relatively low risk associated with
the pathogenesis of bronchial asthma (\5%) [6, 7]. Studies
concerning the role of mutations and gene polymorphisms
with respect to genotype-phenotype relations in bronchial
asthma are conducted at present. Correlations between
molecular changes in numerous gene loci and their con-
sequences are analyzed at the proteomic level. It is
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genesis of the diseases includes a few chromosomes, and
the loci correlating with the phenotype of asthma and atopy
occupy about a half of the genome [1, 8]. The results of the
search for gene or genes predisposing for the development
of atopy or bronchial asthma obtained so far are not con-
sistent, and research is still being conducted in this area
(http://www.ginasthma.com)[ 9].
In view of contemporary research concerning the role of
gene expression in bronchial asthma, the studies investi-
gating the functional signiﬁcance of glucocorticoid recep-
tor gene (NR3C1 nuclear receptor subfamily 3, group C,
member 1 (glucocorticoid receptor)) in steroid-resistant or
difﬁcult-to-treat forms of the disease are particularly
interesting [9–14]. Complete resistance to glucocorticoids
is very rare—it has been estimated to affect less than
1:1000 bronchial asthma patients. Two types of resistance
to glucocorticoids have been distinguished: type 1—resis-
tance induced by cytokines and type 2—resistance asso-
ciated with a mutation of polymorphisms of the NR3C1
gene [9, 10, 15–18]. It should be emphasized, however, that
glucocorticoid resistance is observed in ca. 50% of patients
with severe and difﬁcult-to-treat asthma [9, 10, 15]. The
area of genotype-phenotype correlations with respect to
mutations and polymorphic variants of the NR3C1 gene
extends far beyond the symptoms of bronchial asthma only
[17, 19–24]. The NR3C1 gene is localized on chromosome
5q31-q32 and contains nine exons. As a result of alterna-
tive splicing of the NR3C1 gene, four isoforms of gluco-
corticoid receptor (GCRa, GCRb, GCRd, GCRc) are
formed, out of which only isoform a is active [25–29]. The
glucocorticoid receptor consists of 777 amino acids and
four domains can be distinguished in it: N-terminal AF1
(activation domain 1), DBD (DNA binding domain), NLS
(hinge region), LBD (ligand-binding domain) i C-terminal
AF2 (activation domain 2) [1, 9–11, 13, 15]. The activation
domains determine correct biological mechanisms of
receptor function as well as interactions with transcrip-
tional factors and coactivator proteins [1, 9, 13, 15, 30].
It should be emphasized that the available reports, rel-
atively scarce and sometimes inconsistent, concerning
correlations between the particular polymorphic variants of
the NR3C1 gene with resistance to glucocorticoids and
development of severe/difﬁcult-to-treat asthma, postulate
further thorough research in this ﬁeld.
The aim of the study
The aim of the presented study was to determine the cor-
relations between polymorphism of N363S and ER22/
23EK exon 2 of the NR3C1 gene and resistance to treat-
ment, as well as with the severity proﬁle and extent of
control of the disease in asthma patients. Analysis of cor-
relation between the prevalence of polymorphisms ER22/
23EK and N363S of the NR3C1 gene, and increased sen-
sitivity, or resistance to glucocorticoid therapy was
undertaken in the study.
Materials and methods
The study was approved by the local ethics committee
(Consent of Research Review Board at the Medical Uni-
versity of Lodz, Poland, No RNN/133/09/KE). At the
commencement of the study, participants were invited to
attend voluntarily. Before enrollment, written informed
consent was obtained from every patient.
The study was conducted in a group of 221 patients with
bronchial asthma. Asthma diagnosis was established
according to GINA (The Global Initiative For Asthma)
recommendations, based on clinical asthma symptoms and
lung function test. The level of asthma severity and control
wasdeterminedonthebasisofGINAReportGuidelines.All
the participants underwent subjective examinations (struc-
turalized anamnesis including, besides the element of sub-
jective examination, also the analysis of factors such as:
gender, obesity, tobacco smoking, duration of bronchial
asthma, allergy to house dust mites, animal fur, mould
spores, cockroaches allergens, hypersensitivity to non-ste-
roid anti-inﬂammatory drugs (NSAIDs), etc., in order to
determine their role in the development of resistance to
glucocorticoids, as well as to establish whether they are
primary or secondary to genetic factors in character) and
objective examinations. The results of pulmonary function
testsandallergologictestswereobtainedfromtheindividual
medical records of the patients. If there were no results of
spirometryorallergologictestsavailable,suchexaminations
were additionally performed during the recruitment visit.
Subjects suffering from clinically signiﬁcant exacerbations,
using drugs which might induce resistance to glucocorti-
coids (such as rifampicin, phenobarbital, phenytoin, effe-
drine), subjects with signs of viral infections, either
generalized, or affecting the respiratory tract, as well as
subjects failing to comply with the doctor’s recommenda-
tions,wereexcludedfromthepatientgroup.Thecontrolarm
included a group of 207 healthy adults, who met the fol-
lowing criteria: no history or symptoms of either bronchial
asthma, or other pulmonary diseases, no history or symp-
tomsofallergy,nohistoryorsymptomsofatopicdermatitis,
no history or signs of hypersensitivity to aspirin, negative
results of skin tests for 12 common allergens, no ﬁrst-degree
relatives with bronchial asthma or atopic disorders.
According to the standards developed by the Polish
Society for Pulmonary Diseases, the best result of three
spirometry maneuvers was selected for the analysis of
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123obstructive disorders and disease severity. The correlation
analysis took into consideration FEV1 (forced expiratory
volume) expressed in liters, FEV1% (A/N%—percentage
ratio of the measured to expected value) expressed as per
cent of the expected value and FEV1% FVC index (FEV1
to FVC ratio—forced vital capacity) expressed as absolute
numbers. Spirometry tests were conducted in the Outpa-
tient Department according to ERS (European Respiratory
Society)/ATS (American Thoracic Society) standards, and
allergological tests according to the guidelines of EAACI
(European Academy of Allergy and Clinical Immunology).
The level of asthma control was assessed with Asthma
Control Test, which is clear and easy for patients. The
Asthma Control Test (ACT
TM
) consists of ﬁve questions. It
was developed by Nathan et al. in cooperation with general
practitioners and specialists in diagnostics and therapy of
asthma. Bronchial asthma control level was calculated on
the basis of the following patients’ results obtained in
ACT: 00–19 points—no asthma control, 20–24 points—
partially controlled asthma and 25 points—well-controlled
asthma.
The study was carried out on 428 participants. The
control group consisted of 138 women (66.7%) and 69 men
(33.3%). The youngest participant was 18 years old and the
oldest one 85 years old. The mean age in the control group
was 46.06 years, the median 47.50, SD ± 16.05. The case
group consisted of 140 women (63.3%) and 81 men
(36.7%). The youngest participant was 19 years old and the
oldest one 81 years old. The mean age in the case group
was 48.94 years, the median 51.00, SD ± 15.78. Non-
severe asthma was diagnosed in 147 patients (66.52%)
whereas 74 (33.48%) had a severe form of the disease.
Comprehensive comparison of the analyzed groups is
presented in Tables 1 and 2. The whole group of patients
participating in the study was stratiﬁed and subjected to
statistical analysis.
Venous blood samples were collected from the partici-
pants onto EDTAK3, DNA was obtained from peripheral
blood leukocyte fraction. The genetic material was isolated
using QIAamp DNA Blood Mini Kit (QIAGEN Inc.)
according to the guidelines provided by the manufacturer.
The investigated polymorphisms were analyzed using
PCR-RFLP method.
Exponential ampliﬁcation of DNA segments for N363S
polymorphism was carried out using a forward primer (50-
CCA GTA ATG TAA CAC TGC CCC-30) and a reverse
primer (50-TTC GAC CAG GGG AAG TTC AGA-30)
according to standard PCR protocol. Starter binding to
complementary DNA matrix sites was conducted at 56C.
Ampliﬁed DNA sequences of 357 bp length were obtained.
The material was incubated with FastDigest
 Tsp509I
(TasI) restriction enzyme (Fermentas International INC) at
Table 1 Descriptive statistics
of the analyzed parameters in
controls and cases (general
asthma population in the
presented study)
Parameter Control group Group of bronchial
asthma patients
N 207 221
Gender 138 women: 69 men 140 women: 81 men
Gender 66.7% women: 33.3% men 63.3% women: 36.7% men
Mean age 46.06 years 48.94 years
SD for age ±16.05 years ±15.78 years
Min. age 18 years 19 years
Max. age 85 years 81 years
Kurtosis -0.94 -0.96
Skewness 0.10 -0.19
Median 47.50 51.00
FEV1 (L) mean ± SD 2.95 – 0.78 2.20 – 0.84
FEV1 (L) median 2.85 2.17
FEV1 (%) mean ± SD 96.17 – 12.69 73.13 – 19.38
FEV1 (%) median 96 74
Table 2 Descriptive statistics of the analyzed parameters in cases
(general asthma population in the presented study)
Parameter Group of bronchial
asthma patients
(number)
Group of
bronchial asthma
patients (%)
Asthma 221 100.00
Non-severe asthma 147 66.52
Severe asthma 74 33.48
Chronic mild asthma 34 15.38
Chronic moderate asthma 113 51.14
Chronic severe
steroid-dependent asthma
66 29.86
Chronic severe
steroid-resistant asthma
8 3.62
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12365C for 1 h. DNA fragments with 135, 73, 70, 60 and
19 bp, were obtained as a set of representative, typical
(wild type) alleles, whereas segments of 135, 92
(73 ? 19 bp), 70 and 60 bp, constituted the set of poly-
morphic alleles. RFLP products were separated by elec-
trophoresis on 40% polyacrylamide gel 1:20, stained with
ethidine bromide and observed in UV light. Representative,
typical homozygotes, as well as heterozygotes were
sequenced and used as internal control.
Exponential ampliﬁcation of DNA segments for ER22/
23EK polymorphism was carried out using a forward pri-
mer (50-TGC ATT CGG AGT TAA CTA AAA AG-30) and
a reverse primer (50-ATC CCA GGT CAT TTC CCA TC-
30) according to standard PCR protocol. Starter binding to
complementary DNA matrix sites was conducted at 56C.
Ampliﬁed DNA sequences of 446 bp length were obtained.
The material was incubated with Mnl I restriction enzyme
(Fermentas International INC) at 37C for 20 h. DNA
fragments with 149 and 163 bp (and shorter fragments
containing 50, 49 and 35 base pairs), were obtained as a set
of representative, typical (wild type) alleles, whereas seg-
ments of 163 and 184 bp (and shorter fragments containing
50 and 49 base pairs), constituted the set of polymorphic
alleles. RFLP products were separated by electrophoresis
on 40% polyacrylamide gel 1:60, stained with ethidine
bromide and observed in UV light. Representative, typical
homozygotes, as well as heterozygotes were sequenced and
used as internal control.
The obtained results were subjected to descriptive sta-
tistical analysis with calculation of arithmetic means and
standard deviations. The signiﬁcance of differences
between mean values was determined by means of v
2, with
P\0.05 adopted as the signiﬁcance level.
Results and ﬁndings
In healthy, non-atopic population, within the N363S gene, a
polymorphism of N363S: AA, AG, GG occurring with
0.783/0.159/0.058 frequency, and ER22/23EK: GG, GA,
AA occurring with 0.942/0.058/0.000, were identiﬁed. In
cases (general asthma population analyzed in study) two
polymorphisms were identiﬁed in exon 2 at 1,220 and 198
positionintheNR3C1gene:N363S(AA,AG,GGoccurring
with 0.810/0.122/0.068 frequency) and ER22/23EK (GG,
GA, AA occurring with 0.941/0.059/0.000 frequency).
The group of patients with moderate and severe asthma
stratiﬁed with respect to the extent of control of the disease
according to ACT
TM
is described in Table 3. The distribu-
tion of genotypes for the studied polymorphisms among
moderate uncontrolled and severe uncontrolled asthma
patients was as follows: N363S-AA, AG, GG occurring
with 0.881/0.073/0.046 frequency and ER22/23EK-GG,
GA, AA occurring with 0.963/0.037/0.000 frequency.
Thestudydemonstratednumerousandstrongcorrelations
betweentheprevalenceofmoderateuncontrolledandsevere
uncontrolledasthmaandthecontrolgroupforpolymorphism
N363S of the NR3C1 gene. Such correlations were not
observed for the second analyzed polymorphism-ER22/
23EK. Distribution of N363S polymorphisms of NR3C1
gene was consistent with Hardy–Weinberg equilibrium.
Distribution of ER22/23EK polymorphisms of NR3C1 gene
was not consisted with Hardy–Weinberg equilibrium
[31–33].Table 4andFig. 1illustratedeFinettidistributions
of the investigated genotypes [31, 33–35]. Graph 1 presents
the percentage frequencies of allelic variants of the investi-
gated polymorphisms for the control group and the group of
patients with moderate and severe asthma (ACT
TM
score B 19). Graph 2 presents genotypes of the analyzed
SNPs in the control population and the whole population of
asthma patients.
Signiﬁcant statistical differences between the investi-
gated genotypes were demonstrated (P\0.05). Signiﬁ-
cantly more frequent occurrence of allele A in N363S
polymorphism of the NR3C1 gene was observed in the
population of patients with severe and moderate uncon-
trolled asthma in comparison with the control group
(OR = 1.774, CI: 95% conﬁdence interval, CI =
1.016–3.098, v
2 = 4.15, P = 0.041). In the investigated
N363S polymorphism, allele G was associated with lower
probability of development of the disease (OR = 0.564, CI:
95% conﬁdence interval, CI = 0.323–0.984, v
2 = 4.15,
P = 0.041). For genotype AG versus AA, a signiﬁcant cor-
relation was demonstrated between patients and the control
group with respectto the investigated SNP (OR = 0.409, CI:
95% conﬁdence interval, CI = 0.182–0.922, v
2 = 4.88,
P = 0.027). Additionally, for the investigated N363S poly-
morphism a statistically signiﬁcant correlation was demon-
strated for the following allele variants: [AG ? GG] versus
[AA] (OR = 0.487, CI: 95% conﬁdence interval, CI =
0.250–0.950, v
2 = 4.59, P = 0.032). The details of the
analysis of genotypes for the investigated SNP N363S of the
NR3C1 gene are presented in Table 5 [34–36].
The frequencies of genotypes in the group of patients
with partially controlled and controlled asthma in com-
parison with the control group for N363S polymorphism of
Table 3 Characteristics of the group of patients with moderate and
severe asthma with respect to the extent of control of the disease
according to ACT
TM
Parameter Moderate bronchial
asthma
Severe bronchial
asthma
N 113 74
ACT
TM
score 25 8 (7.08%) 2 (2.70%)
ACT
TM
score 24–20 49 (43.36%) 19 (25.68%)
ACT
TM
score B19 56 (49.56%) 53 (71.62%)
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123the NR3C1 gene were also analyzed demonstrating no
statistically signiﬁcant correlation (P[0.05).
The analysis of ER22/23EK polymorphism of the
NR3C1 gene revealed the absence of any mutants (geno-
type GG). Only wild homozygotes and heterozygotes were
observed. No correlations between the variants of ER22/
23EK polymorphism in the study group and the control
were found (P[0.05). No correlations were demonstrated
taking into consideration the phenotype of asthma severity
and extent of control of the disease in the analyzed
populations.
Discussion
In view of the presented results, the key role is played by
the analysis of factors inﬂuencing the functional
signiﬁcance of the described polymorphisms. Structural
changes within the NR3C1 gene lead to the formation of
various alleles. Single nucleotide polymorphisms (SNPs),
involving substitution of a nucleotide by another one,
commonly occur in the. N363S and ER22/23EK SNPs
affect the coding domains of the NR3C1 gene, signiﬁcantly
changing the sense of the nucleotide sequence and regu-
latory regions of the gene, and modifying its expression.
The occurrence of SNPs results in variability of the ana-
lyzed gene. The observed polymorphic changes in the
length of restriction fragments N363S and ER22/23EK
(RFLP, Restriction Fragment Length Polymorphism) are
located in the coding and regulatory regions of the NR3C1
gene, causing modiﬁcations of function or synthesis of
glucocorticoid receptor. This undoubtedly affects modiﬁ-
cation of phenotypic characteristics of bronchial asthma,
which may be associated with partial or complete resis-
tance to anti-inﬂammatory medications. The loss of control
of asthma symptoms by means of glucocorticoids is asso-
ciated with chronic inﬂammatory condition of the respira-
tory tract, more frequent exacerbations, persistent
bronchial obstruction and marked deterioration of the
patients’ quality of life.
The discussed mutations, or polymorphism, signiﬁcantly
affect gene transcription and RNA splicing process. Recent
studies by van Rossum and Lamberts demonstrated a cor-
relation of ER22/23EK polymorphism with resistance to
glucocorticoids [37]. It is located in exon 2 and consist of
two nucleotide transitions connected with each other in
codons 22 and 23 [37]. Transition in codon 22 causes no
Table 4 Description of Hardy–Weinberg equilibrium for control and
cases groups (moderate and severe asthma, ACT
TM
score B19)
SNPs Tests for deviation from Hardy–Weinberg equilibrium
Controls Cases
N363S nAA = 162 (153.92) nAA = 96 (91.74)
nAG = 33 (49.15) nAG = 8 (16.51)
nGG = 12 (3.92) nGG = 5 (0.74)
f_a1 = 0.86 ± 0.020 f_a1 = 0.92 ± 0.023
F = 0.32862 F = 0.51556
P = 2.268e-06
(Pearson)
P = 7.343e-08
(Pearson)
P = 0.000035 (Llr) P = 0.000058 (Llr)
P = 0.000035 (Exact) P = 0.000084 (Exact)
ER22/23EK nGG = 194 (194.17) nGG = 104 (104.04)
nGA = 12 (11.65) nGA = 4 (3.93)
nAA = 0 (0.17) nAA = 0 (0.04)
f_a1 = 0.97 ± 0.008 f_a1 = 0.98 ± 0.009
F =- 0.03000 F =- 0.01887
P = 0.666773 (Pearson) P = 0.844547 (Pearson)
P = 0.548476 (Llr) P = 0.783524 (Llr)
P = 1.000000 (Exact) P = 1.000000 (Exact)
Tests for deviation from Hardy–Weinberg equilibrium were per-
formed using free software provided by Institut fu ¨r Humangenetik,
Helmholtz Zentrum Mu ¨nchen, Deutsches Forschungszentrum fu ¨r
Gesundheit und Umwelt (Germany)
The tests for association are adapted from Sasieni (1997) [36]
f_a1 Frequency of allele 1 ± SD
F Inbreeding coefﬁcient
P (Pearson) Pearson’s goodness-of-ﬁt chi-square (degree of freedom
= 1)
P (Llr) Log likelihood ratio chi-square (degree of freedom = 1)
P (Exact) Exact test
n number
Fig. 1 Description of diagram: black line controls; blue line cases.
De Finetti diagram with Hardy–Weinberg parabola was drawn using
free software provided by Institut fu ¨r Humangenetik, Helmholtz
Zentrum Mu ¨nchen, Deutsches Forschungszentrum fu ¨r Gesundheit
und Umwelt (Germany). (Color ﬁgure online)
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123amino acid substitution, whereas transition in codon 23
causes substitution of arginine with lysine, which may lead
to a change in the tertiary structure of the receptor domain
responsible for activation of transcription [38]. Transition
in codon 23 may also cause a change in the secondary
structure of glucocorticoid receptor mRNA, and, conse-
quently, initiation of translation from 1 or 27 methionine
[39, 40]. Moreover, the aforementioned substitution in
codon 23 may affect the stability of glucocorticoid receptor
mRNA [39, 40]. Association of that polymorphism with
resistance to glucocorticoids, as well as with more favor-
able metabolic proﬁle in healthy population has also been
described [39, 40].
One, or more of the discussed SNPs may occur in iso-
lation or in combination, affecting signiﬁcantly the NR3C1
gene transcription and RNA splicing process.
It is interesting that N363S and ER22/23EK SNPs
consistently modify the N-terminal AF1 glucocorticoid
Graph 1 Descriptive statistics
of the analyzed allele of N363S
and ER22/23EK polymorphisms
of NR3C1 gene in controls and
cases (moderate and severe
asthma, ACT
TM
score B19)
Graph 2 Descriptive statistics
of the analyzed allele of N363S
and ER22/23EK polymorphisms
of NR3C1 gene in controls and
cases (general asthma
population in the presented
study)
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123receptor domain, thus affecting activation of the receptor
function and the potential for interactions with transcrip-
tional factors [1]. As a result of alternative splicing of
mRNA, defective glucocorticoid receptor isoforms may be
formed. Polymorphisms N363S and EK22/23EK of exon 2
of the NR3C1 gene are known to modify the protein
structure within the AF1 domain, affecting the antigen
properties of the receptor [1].
The in vivo studies conducted by Huizenga et al. dem-
onstrated a correlation of N363S polymorphism with
increasedsensitivitytoglucocorticoids[30].IntheHuizenga
et al. performed study, it was observed that individuals car-
ryingthisN363Spolymorphism(alleleG)seemedhealthyat
clinical examination but had a higher sensitivity to exoge-
nously administered glucocorticoids [32]. In the presented
study, it was shown that appearance of allele A in the
investigatedN363Spolymorphismcorrelatedwithstatistical
signiﬁcance with increased risk of more severe phenotypic
form of asthma and loss of the possibility to reduce its
symptoms with anti-inﬂammatory drugs. Obviously, the
severity of the disease and the possibility of its control are
affectedbymultiplefactors,bothenvironmentalandgenetic.
The analyzed population of patients (moderate and severe
uncontrolledasthma) wasselectedfromamongallbronchial
asthma patients. Signiﬁcant statistical correlations were
obtained only for the selected phenotypic subgroup of
patients,andnotforthewholestudiedpopulation.Nosimilar
correlations were observed for the whole study group.
Thus, it can be concluded that N363S SNP may deter-
mine only the disease phenotypes from moderate to severe,
but only uncontrolled forms (ACT
TM
score B19). Statistical
analysis demonstrated signiﬁcant correlations only for the
patients with uncontrolled or insufﬁciently treated patients
enrolled in the study, which may suggest decreased sensi-
tivity of the glucocorticoid receptor. In fact, patients with
asthma control score according to ACT
TM
B19 are regarded
as treated not intensively enough. Such patients should be
shifted to more intensive treatment, as they suffer from
more severe asthma than indicated by the proﬁle of the
received medication. This phenomenon reﬂects underesti-
mation of severe asthma. Incorrect qualiﬁcation of patients
to the particular categories may falsify the actual percent-
age distribution of bronchial asthma severity grades. The
above may be important for interpretation of genetic
investigations. The RFLP marker for N363S SNP seems
therefore to have a clinical signiﬁcance. It may be useful
for identiﬁcation of patients with severe asthma proﬁle,
requiring more intensive treatment from the very
beginning.
Nevertheless, it should be stated that bronchial asthma is
a disease determined by multiple factors and that asth-
matics constitute a heterogeneous group of patients.
Table 5 Description of tests for association (CI 95% conﬁdence interval) for control and cases groups (ACT
TM
score B19)
SNP Tests for association (CI 95% conﬁdence interval)
Allele freq. difference Heterozygous Homozygous Allele positivity Armitage’s trend test
N363S Risk allele G
[G] vs. [A] [AG] vs. [AA] [GG] vs. [AA] [AG ? GG] vs. [AA] Common odds ratio
Odds ratio = 0.564 Odds ratio = 0.409 Odds ratio = 0.703 Odds ratio = 0.487 Odds ratio = 0.721
CI = [0.323–0.984] CI = [0.182–0.922] CI = [0.240–2.057] CI = [0.250–0.950]
v
2 = 4.15 v
2 = 4.88 v
2 = 0.42 v
2 = 4.59 v
2 = 3.01
P = 0.04170 P = 0.02710 P = 0.51829 P = 0.03220 P = 0.08297
Risk allele A
[A] vs. [G] [AG] vs. [GG] [AA] vs. [AG] [AA ? AG] vs. [GG] Common odds ratio
Odds ratio = 1.774 Odds ratio = 0.582 Odds ratio = 1.422 Odds ratio = 1.280 Odds ratio = 1.366
CI = [1.016–3.098] CI = [0.159–2.131] CI = [0.486–4.160] CI = [0.439–3.732]
v
2 = 4.15 v
2 = 0.68 v
2 = 0.42 v
2 = 0.21 v
2 = 3.01
P = 0.04170 P = 0.41054 P = 0.51829 P = 0.65044 P = 0.08297
Tests for association were performed using free software provided by Institut fu ¨r Humangenetik, Helmholtz Zentrum Mu ¨nchen, Deutsches
Forschungszentrum fu ¨r Gesundheit und Umwelt (Germany)
The tests for association are adapted from Sasieni (1997) [36]
f_a1 Frequency of allele 1 ± SD
F Inbreeding coefﬁcient
P (Pearson) Pearson’s goodness-of-ﬁt chi-square (degree of freedom = 1)
P (Llr) Log likelihood ratio chi-square (degree of freedom = 1)
P (Exact) Exact test
n number
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123Conclusions
A correlation was demonstrated between N363S poly-
morphism of the NR3C1 gene and moderate/severe
uncontrolled bronchial asthma phenotype. It was conﬁrmed
in a large group of subjects that N363S SNP may play an
important role in the development of difﬁcult-to-treat/
treatment-resistant disease. No such correlation was dem-
onstrated for the second investigated polymorphism.
As it is observed not only in bronchial asthma, but also
in many other diseases (rheumatoid arthritis, leukemias,
graft rejection and others), steroid resistance requires fur-
ther thorough studies, addressing in particular the role of
polymorphisms of the NR3C1 gene, which may become
the target for novel therapies. Evaluation of its usefulness
in this respect requires further analyses.
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